Epigenetic pharmacotherapy for substance use disorder

Biochem Pharmacol. 2019 Oct:168:269-274. doi: 10.1016/j.bcp.2019.07.012. Epub 2019 Jul 12.

Abstract

Identifying novel therapeutics for the treatment of substance use disorder (SUD) is an area of intensive investigation. Prior strategies that have attempted to modify one or a few neurotransmitter receptors have had limited success, and currently there are no FDA-approved medications for the treatment of cocaine, methamphetamine, and marijuana use disorders. Because drugs of abuse are known to alter the expression of numerous genes in reward-related brain regions, epigenetic-based therapies have emerged as intriguing targets for therapeutic innovation. Here, I evaluate potential therapeutic approaches and challenges in targeting epigenetic factors for the treatment of SUD and highlight examples of promising strategies and future directions.

Keywords: Addiction; Cocaine; Epigenetics; Substance use disorder; Therapeutics.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Behavior, Addictive / drug therapy*
  • Behavior, Addictive / genetics*
  • Behavior, Addictive / metabolism
  • Brain / drug effects*
  • Brain / metabolism
  • Epigenesis, Genetic / drug effects*
  • Epigenesis, Genetic / physiology
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Narcotic Antagonists / pharmacology
  • Narcotic Antagonists / therapeutic use
  • Nicotinic Antagonists / pharmacology
  • Nicotinic Antagonists / therapeutic use
  • Substance-Related Disorders / drug therapy*
  • Substance-Related Disorders / genetics*
  • Substance-Related Disorders / metabolism

Substances

  • Histone Deacetylase Inhibitors
  • Narcotic Antagonists
  • Nicotinic Antagonists